U.S. markets close in 4 hours 31 minutes

Nymox Pharmaceutical Corporation (NYMX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.6100-0.0100 (-0.62%)
As of 11:24AM EDT. Market open.

Nymox Pharmaceutical Corporation

Bay & Deveaux Streets
2nd Floor
800 936 9669

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Paul AverbackFounder, Chairman, CEO & PresN/AN/A1951
Mr. Erik DanielsenCFO & Controller535kN/A1963
Mr. Randall J. Lanham J.D., Esq.Gen. Counsel, Sec. & Director324.77kN/A1964
Ms. Lin DoddQA and Compliance Mang.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.

Corporate Governance

Nymox Pharmaceutical Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.